Abstract
This article gives an overview about the development of human therapeutic antibodies generated by phage display. After an introduction to the method, the focus is on approved antibodies and those currently in clinical trials, 14 of which are described in detail.
Keywords: Therapeutic Antibodies, phage display, clinical trials, CHO producer cells, immune system, GENE LIBRARIES
Current Pharmaceutical Biotechnology
Title: Phage Display Derived Therapeutic Antibodies
Volume: 9 Issue: 6
Author(s): Holger Thie, Torsten Meyer, Thomas Schirrmann, Michael Hust and Stefan Dubel
Affiliation:
Keywords: Therapeutic Antibodies, phage display, clinical trials, CHO producer cells, immune system, GENE LIBRARIES
Abstract: This article gives an overview about the development of human therapeutic antibodies generated by phage display. After an introduction to the method, the focus is on approved antibodies and those currently in clinical trials, 14 of which are described in detail.
Export Options
About this article
Cite this article as:
Thie Holger, Meyer Torsten, Schirrmann Thomas, Hust Michael and Dubel Stefan, Phage Display Derived Therapeutic Antibodies, Current Pharmaceutical Biotechnology 2008; 9 (6) . https://dx.doi.org/10.2174/138920108786786349
DOI https://dx.doi.org/10.2174/138920108786786349 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Small Molecules Targeting p53 to Improve Antitumor Therapy
Mini-Reviews in Medicinal Chemistry Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Genotoxicity in Alzheimers Disease: Role of Amyloid
Current Alzheimer Research Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Melatonin Prevents Neddylation Dysfunction in Aβ42-Exposed SH-SY5Y Neuroblastoma Cells by Regulating the Amyloid Precursor Protein- Binding Protein 1 Pathway
Current Alzheimer Research Metabolic Analysis of Triptolide Microspheres in Human, Dog, Rabbit and Rat Liver Microsomes with UPLC-MS/MS Method
Current Pharmaceutical Analysis A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
Current Alzheimer Research MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Current Alzheimer Research Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry